Discover and develop innovative therapeutics for inflammatory bowel diseases (IBD) like ulcerative colitis and Crohn's disease. Now — the numbers.
The company is still in the product-building phase: its spending runs far above its sales. That only changes once the product starts selling at scale.
At this burn rate the cash pile isn’t the pressing question — for now, time is on the company’s side.
This company is not turning a profit, so the market is pricing its sales instead: 1,403.8× for every dollar of annual revenue.
Analysts' average target sits 31% below today's price.
angles, checked one by one.
The 4 that stand out are on screen; the rest came back neutral.
The council scores out of 10; report-card grades are out of 100.
The stock trades near its peak today. For long-term holders the ride has paid off so far — though past performance guarantees nothing about the future.
Sales run at $6.8M a year. A small number, but proof the product has real buyers.
There is $695.8M in the vault; even if every debt were paid off, $666.2M would remain.
A loss of $141.8M against $6.8M in annual sales.
The stock trades 31% above the average analyst price target.
We don’t have a report card for this stock yet — the data isn’t mature enough to grade. No grade is information too: it means the evidence is thin.
One-line summary: few numbers, an untested story. Keep watching.
Not covered, because the filings we hold do not carry it: the revenue breakdown.